
Mati Therapeutics: Innovating non-invasive, sustained drug delivery for ocular diseases.
Mati Therapeutics, headquartered in Austin, Texas, is focused on developing a non-invasive sustained drug delivery platform to treat ocular diseases, particularly glaucoma. The company's mission is to improve the quality of life for individuals with vision impairment by providing innovative solutions that address preventable or correctable causes of blindness and vision loss. Their market focus includes patients suffering from glaucoma and other ocular conditions that require consistent and effective treatment.
Mati Therapeutics has made significant strides in the field of ophthalmology by advancing their sustained drug delivery technology. This innovation aims to reduce the frequency of treatments and improve patient compliance, ultimately leading to better health outcomes. The company’s impact is underscored by its commitment to addressing the global need for effective ocular therapies, contributing to the overall well-being of individuals with vision impairments.

Ocular Therapeutix
ocutx.com

TherOptix

Imagen Biotech

Vitranu
vitranu.com

TearClear
tearclear.com

Perfuse Therapeutics

EyeCyte
eyecyte.com

MediPrint Ophthalmics

Spyglass Pharma
spyglasspharma.com

LumiThera
lumithera.com

Iacta Pharmaceuticals

Amorphex Therapeutics
amorphexusa.com

Ocumension Therapeutics

Mahzi Therapeutics
mahzi.com

OcuTerra Therapeutics
ocuterratx.com
Companies similar to Mati Therapeutics include Ocular Therapeutix, TherOptix, Imagen Biotech and Vitranu.
Mati Therapeutics was founded in 2012.
Mati Therapeutics' headquarters is located in Austin, TX, US.
Mati Therapeutics' most recent funding round was for $165k (USD) in May 2019.
As of May 11, 2019, Mati Therapeutics has raised a total of $1.6M (USD).
Mati Therapeutics has 30 employees as of Feb 5, 2024.